Masseter and Bruxism — Anatomy and Treatment
Teeth grinding, tension headaches, a prominent lower jaw from masseter hypertrophy: how targeted treatment of the chewing muscle with botulinum toxin type A works — and when it is genuinely indicated.
A note on terminology: Many patients search for “Botox” — a brand name of one single product that has become a colloquial umbrella term. The active substance is botulinum toxin type A, contained in several licensed medicinal products. All of them are prescription-only and are injected exclusively by the physician after a medical examination. This page uses the substance name throughout — it refers to the same treatment commonly known as a Botox treatment.
Masseter and Bruxism
What you will find here: anatomy of the most powerful chewing muscle (43% of bite force), the distinction between sleep and awake bruxism, individual dosing logic, three parallel effects (functional + aesthetic + pain modulation), complications with a focus on asymmetric smile. Booking and fee information on the treatment page.
Bruxism — nocturnal grinding or daytime clenching — is a widespread, often unnoticed dysfunction of the masticatory system. The involuntary tonic tension of the masseter muscle generates enormous forces that wear down teeth, strain the jaw joints and transmit pain along trigeminal pathways. Targeted weakening of the muscle with botulinum toxin type A does not resolve the cause — but it does take the pressure out of the system. Three effects arise in parallel: functional relief, aesthetic narrowing of the cheek (slim-face effect), and a possible reduction in trigeminal pain comorbidities.
The most powerful chewing muscle
The masseter muscle is a rectangular, powerful chewing muscle with two parts: a superficial and a deep one. It originates at the zygomatic arch (cheekbone) and inserts at the angle of the mandible and the lateral surface of the mandibular ramus. It is innervated by the trigeminal nerve (mandibular branch, V3).
Share of total bite-force output
| Muscle | Share of bite force | Function |
|---|---|---|
| Masseter muscle | approx. 43% | Main muscle of jaw elevation, most powerful biting muscle |
| Temporalis muscle | approx. 36% | Stabilization of the lower jaw, retraction |
| Medial pterygoid muscle | approx. 21% | Internal jaw elevation, combined action |
Masseter hypertrophy as a visible sign
Long-term bruxism leads to a thickening of the muscle mass — the masseter becomes measurably thicker (documentable by ultrasound). This hypertrophy is usually bilateral, but depending on chewing habits can also occur unilaterally. Clinically it becomes visible as an angular, square cheek contour — sometimes perceived as a cosmetically undesired “heavy” lower jaw area, sometimes understood simply as a typical appearance without any disease value.
What bruxism is — and what it is not
Bruxism is a repetitive chewing-muscle activity that manifests as grinding, clenching or bracing the jaws. The international classification distinguishes two main forms whose pathophysiology only partly overlaps:
| Form | Characteristics | Clinical picture |
|---|---|---|
| Sleep bruxism | Occurs unconsciously during sleep, often with an audible grinding sound (noticed by a partner). Associated with micro-arousals. | Morning jaw fatigue, “tense” waking, morning headaches, tooth wear |
| Awake bruxism | During the day, often triggered by stress. Usually clenching rather than grinding, no sound. | Afternoon jaw fatigue, pressure pain lateral to the jaw angle, temple headache |
Diagnostic criteria
- History and partner interview — grinding sounds during sleep, morning symptoms
- Clinical examination — palpation of the masseter muscle (hypertrophy, pressure pain), tooth wear (attrition), bite-mark impressions on the buccal mucosa, tongue scalloping
- Functional diagnostics — mouth-opening width, jaw-joint sounds, pressure trigger points
- Fonseca Anamnestic Index — structured questionnaire for quantifying temporomandibular dysfunction (TMD)
- Optional: ultrasound — objective measurement of masseter thickness (Erdil et al. 2022 and subsequent studies establish this methodology)
Three parallel effects of the treatment
Botulinum toxin type A acts on the masseter as on any other skeletal muscle: it inhibits acetylcholine release at the neuromuscular junction and thereby reduces muscle contractility. What makes this treatment special is its simultaneous effect on three different levels:
Effect 1 — Functional
- Reduction of bite force to a healthy level (typically a 30–50% weakening of maximum voluntary contraction)
- Reduction in nocturnal grinding intensity — studies show measurable reduction in EMG activity during sleep
- Relief of the jaw joints — less compression, fewer clicking sounds
- Protection of tooth substance — less abrasion, fewer enamel fractures
Effect 2 — Aesthetic (slim-face effect)
- Reduction of muscle hypertrophy — the muscle becomes measurably thinner
- Narrowing of the lower face — the angular jaw area is softened in contour
- Study data: volume reduction of approximately 30–31% at 3 months, depending on baseline thickness
- In patients with pronounced hypertrophy, this effect is often the subjectively strongest one — even though the functional relief is medically more important
Effect 3 — Pain-modulating (trigeminal)
- The masseter is innervated via the trigeminal nerve (V3) — the same pain pathways that are sensitized in migraine and tension headache
- Reduction of tonic trigeminal activation may contribute to relief of accompanying headaches
- Patients frequently report reduced morning headaches and fewer migraine triggers after masseter treatment
- This effect is anecdotally documented, not established in randomized trials specifically for migraine reduction through masseter BTX alone
Dosing logic and injection scheme
Dose-finding at the masseter is a balance — too little does not work sufficiently, too much can lead to chewing weakness or an asymmetric smile. Unlike facial-expression treatments, a powerful, deep muscle is treated here that tolerates higher doses.
Anatomical localization of the injection points
The injections are not made “anywhere in the muscle” — there is a defined safe zone identified by palpation and marking:
- Below: at least 1 cm above the lower jaw margin (protecting the mandibular nerve, salivary glands)
- Anterior: at least 1 cm behind the anterior masseter border (protecting the risorius muscle, zygomaticus major — critical for the smile)
- Posterior: at least 1 cm in front of the posterior ramus border (protecting the parotid gland, major vessels)
- Superior: below the zygomatic arch
- Depth: into the deep masseter portion, about 1–1.5 cm below the skin (aspiration before injection)
Duration of effect and course
| Time point | Observation |
|---|---|
| Day 1–3 | No visible effect yet, possibly local pressure pain at injection sites |
| Day 7–14 | First effect noticeable — reduced morning jaw fatigue, less grinding pressure |
| Week 4–8 | Full functional effect. Slim-face effect becomes measurable (ultrasound) |
| Month 3 | Maximum volume reduction of the masseter (Erdil et al. 2022: significant) |
| Month 4–6 | Gradual waning of the effect. Repeat treatment indicated if symptoms recur |
Migraine comorbidity and combined treatment
Migraine and bruxism frequently occur together — various studies show that more than half of all migraine patients also show signs of bruxism, and conversely many bruxism patients report chronic headaches that do not fit the classic migraine diagnostic pattern.
Pathophysiological link
Both indications share the same nerve: the trigeminal nerve. Its third branch (V3) provides the motor supply to the masseter, while its first and second branches (V1 and V2) carry pain sensation from the forehead, temple and facial region. Tonic overactivation in the V3 branch can sustain central sensitization processes throughout the trigeminal system — and thereby increase migraine sensitivity.
In migraine patients, the masseter is always palpated at the initial consultation. Hypertrophy, pressure pain and signs of bruxism are clear indicators for extending the treatment scheme.
— from: Migraine editorial, Practice of Dr. Thomas Ackermann
Combined treatment in practice
In patients with concurrent bruxism and headache symptoms, both indications are often treated at the same appointment:
| Constellation | Treatment strategy |
|---|---|
| Pure bruxism without headache | Masseter treatment alone, 25–40 U per side |
| Bruxism + episodic headaches | Masseter + possibly forehead/glabella, honest counselling on the possible co-effect |
| Bruxism + chronic migraine | Full PREEMPT scheme with masseter extension |
| Hypertrophy without clinical symptoms (purely aesthetic) | Masseter treatment with slim-face goal, individual dose |
The decision on extending treatment is made following palpatory findings, history, and a detailed consultation. A bidirectional interlocking between migraine treatment logic and bruxism treatment is the standard approach in the Ackermann practice.
Complications and safety aspects
Masseter treatment is overall safe and well tolerated, but has a few specific risks that are clearly explained during the consultation.
| Observation | Frequency | Duration |
|---|---|---|
| Temporary chewing weakness | common (intended effect), occasionally subjectively stronger than desired | 4–6 weeks, subsides with the toxin effect |
| Asymmetric smile (risorius/zygomaticus involvement) | rare, with too-anterior injection | 3–6 weeks, fully reversible |
| Local pressure pain at injection sites | common, brief | 2–4 days |
| Bruising | occasional | 5–10 days |
| Altered bite perception (“odd feeling when chewing”) | occasional in the first weeks | 1–3 weeks, adaptation |
| Jaw-joint clicking (temporarily stronger) | rare | subsides after 4–6 weeks |
| Reduced salivary production | very rare — only with too-posterior injection near the parotid | 4–8 weeks |
Avoiding the risorius risk
The asymmetric smile arises when botulinum toxin, through diffusion or too-anterior injection, also weakens the risorius muscle or zygomaticus major. These muscles are responsible for the lateral pulling-up of the corners of the mouth. Co-weakening leads to a crooked smile, which is very disturbing for the patient — even though it is fully reversible. Avoidance strategy: precise palpation of the anterior masseter border, maintaining a minimum distance of 1 cm, injection into the deep muscle portion.
What the treatment is not
Five precise distinctions
- It is not a substitute for an occlusal splint. For nocturnal grinding, an occlusal splint mechanically protects the teeth — it prevents abrasion. Botulinum toxin reduces the force but cannot replace the splint’s function. Both procedures are often recommended in combination.
- It does not cure the cause of bruxism. Bruxism often has psychological components (stress, tension), sleep disorders, or muscular dysfunctions. BTX treatment takes the pressure out of the symptom — the underlying factors remain unchanged. Stress management, physiotherapy and, where appropriate, dental follow-up belong to the complete treatment concept.
- It is not a first-line therapy for mild bruxism. With occasional grinding episodes and no clinical symptoms, BTX is not necessarily needed. An occlusal splint, physiotherapy and lifestyle adjustments are often sufficient. BTX becomes relevant with moderate to severe bruxism with clinical symptoms (pain, hypertrophy, functional limitation).
- It is not primarily approved for awake bruxism. The evidence base is stronger for sleep bruxism. For conscious daytime clenching (awake bruxism), behavioral therapy and stress management are primarily indicated — but BTX can be worth trying in treatment-resistant cases.
- It does not change bone structure. The slim-face effect arises from reduction of muscle mass, not bone remodeling. With a very pronounced jaw angle with a bony component, BTX alone is not sufficient — jaw-surgical procedures would be the structural answer in such cases.
What patients want to understand more deeply
Will I still be able to eat normally after treatment?
Yes. The reduction in bite force is intentional, but it typically lies at 30–50% — far below the level that would make normal eating difficult. You will still be able to chew steaks, hard rolls and nuts without problems. A temporary “soft” sensation in the first few days is possible; it disappears quickly. With too high a dose, more significant chewing limitations can occur in rare cases — which is why dosing is conservative and topped up if needed.
When will I see the slim-face effect?
The first changes are noticeable after 4–6 weeks; the maximum volume reduction occurs between month 2 and 3 after treatment. On ultrasound the muscle thinning is then clearly measurable. Anyone wanting a pronounced slim-face effect often benefits only after 2–3 treatment cycles — the muscle mass reduces cumulatively.
Can I combine the treatment with filler?
Yes, that is a common approach. In patients whose face becomes narrower through masseter weakening, cheek filler can simultaneously accentuate the midface — creating a more harmonious overall picture. The filler treatment typically takes place 4–8 weeks after the masseter treatment, once the slim-face effect can be assessed.
Is the treatment covered by health insurance?
With a documented medical indication (bruxism with clinical symptoms, documented TMD, pronounced masseter hypertrophy), reimbursement is possible on a case-by-case basis. The exact terms vary between insurers. In practice this is discussed individually — many patients choose the treatment as a self-pay service, some submit it to their insurer. Medical documentation of the diagnosis is a prerequisite.
Does the treatment really help against my headaches?
Patients with bruxism and accompanying headaches frequently report relief in headache frequency and intensity after masseter treatment. This observation is anecdotally documented, not established in randomized trials specifically for headache reduction through masseter BTX alone. Anyone suffering primarily from migraine should consider migraine treatment — often combined with masseter extension.
What happens if I stop the treatment?
The masseter fully regenerates. Over 4–6 months, bite force returns to baseline, and muscle hypertrophy can also recur if the bruxism behavior continues. There is no “rebound” — bite force does not become stronger than before. Anyone wanting a lasting benefit typically treats every 4–6 months; over time the intervals can lengthen.
What about the jaw joint — can’t it become stiffer?
On the contrary: the pressure reduction on the jaw joint often relieves it. The typical observation is a reduction in clicking sounds and mouth-opening complaints. Temporarily, in the first 1–2 weeks, altered bite perception can occur — that is normal and self-regulates.
How does the treatment differ from filling with filler?
Fillers enlarge or reshape structures through volume addition. With bruxism it is the opposite — the reduction of muscle mass. BTX and filler are complementary procedures with different mechanisms of action and are often combined sequentially (first masseter reduction, then targeted cheek accentuation).
What the treatment is scientifically based on
Erdil D et al., 2022 — Masseter thickness and bruxism
The Evaluation of the Relationship between Changes in Masseter Muscle Thickness and Tooth Clenching Habits of Bruxism Patients Treated with Botulinum Toxin A. Journal of Medical Ultrasound 31(1): 22–28. Prospective study at the Ankara University Faculty of Dentistry with 38 patients with sleep bruxism enrolled; the completed study population comprised 25 patients (23 women, 2 men) after loss to follow-up. Ultrasound measurement of masseter thickness before, and 3 and 6 months after BTX treatment. Result: statistically significant reduction in muscle thickness (P < 0.05), in parallel with a significant reduction in the Fonseca bruxism score (50.00 → 42.00, P = 0.015). 3 of 11 patients with moderate TMD improved to mild or TMD-free.
To EW, Ahuja AT, Ho WS et al. — EMG and ultrasound follow-up
Ultrasound records and EMG evaluation 3 months after BTX-A application into the masseter showed a 31% reduction in masseter muscle volume. It was found that 6 of the 9 masseter muscles examined retained their atrophic state.
Yu CC et al. — CT volumetry after masseter treatment
Investigation of the change in masseter muscle volume using CT (computed tomography). The study documented a statistically significant mean volume reduction of about 30% after BTX-A application, with the maximum reduction at the 3rd month.
Consensus recommendations Sommer/Bergfeld/Sattler, 2007
Konsensusempfehlungen zum Gebrauch von Botulinumtoxin A in der ästhetischen Medizin. JDDG Supplement 1, Band 5. Rates bruxism as “a non-aesthetic indication affecting the facial muscles that responds very well to treatment” — refers to neurological sources for further detail.
Bruxism treatment with botulinum toxin is clinically well established and documented by multiple objective follow-up studies. The works cited here represent the main methodological standards (ultrasound, CT, EMG for follow-up measurement) — a comprehensive Cochrane analysis of bruxism treatment with BTX is not yet available, but is to be expected in the coming years.
Would you like to discuss the treatment in person?
The treatment page with booking process, requirements and fee information is here:
Teeth grinding · Treatment overview
For an overview of all wrinkle treatments with botulinum toxin in Herzogenaurach, see the category page.
For patients from the Erlangen area: botulinum toxin type A near Erlangen.
Dr. med. Thomas Ackermann
Specialist in Anaesthesiology · Medical Director, Harmonie der Ästhetik
The masseter is a powerful muscle with clearly defined anatomical borders — and that is exactly what makes the treatment so controllable. Palpation of the muscle borders, precise injection depth, careful dose-finding — this is anaesthesiological routine, applied to the chewing apparatus. The combination with migraine treatment arises organically in many cases — both indications share the same trigeminal pain pathways and respond to the same pharmacological logic. This page was last reviewed on 17 May 2026.
Wrinkles & Muscle Relaxants
HIFU Lifting
Primary Care Support
Hair Loss
Infusion Therapy
Tension & Pain
Skin Diseases
